23 June 2025
Welsh Government has approved advice from the All Wales Medicines Strategy Group (AWMSG) for three medicines.
- Teriparatide is recommended to treat osteoporosis in men who have an increased risk of fracturing a bone.
- Panitumumab (Vectibix®) is recommended to treat a type of metastatic colorectal cancer originating in the left side of the large intestine, if a liquid biopsy confirms the cancer is RAS wildtype and has previously responded to treatment with a medicine targeting EGFR proteins on cancer cells plus at least one other medicine. Panitumumab (Vectibix®) is not licensed for the rechallenge of metastatic colorectal cancer and is being used ‘off-label’. Prescribers are reminded that the risks and benefits for its use should be clearly stated and discussed with their patients and carers to allow informed consent, and prescribers should consult the guidelines on prescribing unlicensed medicines. Read our patient information leaflet about unlicensed and off-label use of medicines.
- Trametinib (Mekinist®) is recommended to treat low-grade serous ovarian cancer (known as LGSOC) when it has not responded to at least one chemotherapy treatment that included a platinum-based medicine. Trametinib (Mekinist®) is not licensed to treat LGSOC and is being used ‘off-label’. Prescribers are reminded that the risks and benefits for its use should be clearly stated and discussed with their patients and carers to allow informed consent, and prescribers should consult the guidelines on prescribing unlicensed medicines. Read our patient information leaflet about unlicensed and off-label use of medicines.
AWTTC’s Patient Access to Medicines Service (PAMS) supports the AWMSG to assess and monitor new medicines in Wales.